With the business potentially at an important milestone, we thought we'd take a closer look at Echo IQ Limited's (ASX:EIQ) future prospects. Echo IQ Limited provides artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia and the United Kingdom. On 30 June 2025, the AU$152m market-cap company posted a loss of AU$13m for its most recent financial year. The most pressing concern for investors is Echo IQ's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Echo IQ is bordering on breakeven, according to the 2 Australian Software analysts. They expect the company to post a final loss in 2026, before turning a profit of AU$44m in 2027. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 51% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
Underlying developments driving Echo IQ's growth isn’t the focus of this broad overview, though, keep in mind that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for Echo IQ
Before we wrap up, there’s one aspect worth mentioning. Echo IQ currently has no debt on its balance sheet, which is rare for a loss-making growth company, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
This article is not intended to be a comprehensive analysis on Echo IQ, so if you are interested in understanding the company at a deeper level, take a look at Echo IQ's company page on Simply Wall St. We've also compiled a list of relevant factors you should further research:
- Historical Track Record: What has Echo IQ's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Echo IQ's board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Valuation is complex, but we're here to simplify it.
Discover if Echo IQ might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:EIQ
Echo IQ
Engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia.
Exceptional growth potential with excellent balance sheet.
Market Insights
Community Narratives

